Literature DB >> 3040376

Identification and localization of glucagon-like peptide-1 and its receptor in rat brain.

I Shimizu, M Hirota, C Ohboshi, K Shima.   

Abstract

The existence and distribution of glucagon-like peptide-1 (GLP-1) and its receptor in rat brain in relation to that of glucagon were examined. The concentration of GLP-1 immunoreactivity (GLP-1-IR), measured by a specific and sensitive RIA established in this study with anti GLP-1 serum (LMT-01), was found to be highest in the thalamus-hypothalamus, followed by the medulla oblongata. The distribution of glucagon-like immunoreactivity was similar to that of GLP-1-IR. However, appreciable glucagon immunoreactivity was detected only in the thalamus-hypothalamus. Gel filtration analysis showed the presence of GLP-1-IR of various molecular weights in the extract of thalamus-hypothalamus including that eluted at the same position as synthetic GLP-1 (1-37); moreover, HPLC analysis also confirmed the presence of GLP-1-IR, eluted at the exact position as synthetic GLP-1 (1-37). The distribution of receptors for GLP-1 corresponded with that of GLP-1-IR in the rat brain, except in the pituitary gland. The distribution of these receptors was also similar to that of glucagon receptors. The thalamus-hypothalamus, pituitary gland, and medulla oblongata were rich in GLP-1 and glucagon-binding sites. The binding affinities of GLP-1 and glucagon were in the nanomolar range [disocciation constant Kd approximately equal to 4 nM]. The presence of specific, high affinity receptors for GLP-1 was confirmed by demonstrating that GLP-1 stimulated cAMP formation in the thalamus-hypothalamus and the pituitary gland. The concentration of GLP-1 required for half-maximal stimulation of cAMP formation in these regions was about 1 nM. These results suggest that GLP-1 may be synthesized in certain parts of the brain and play a role as a neurosignal transmitter.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040376     DOI: 10.1210/endo-121-3-1076

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  35 in total

1.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.

Authors:  A Wettergren; M Wøjdemann; S Meisner; F Stadil; J J Holst
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

Authors:  Claude Knauf; Patrice D Cani; Christophe Perrin; Miguel A Iglesias; Jean François Maury; Elodie Bernard; Fadilha Benhamed; Thierry Grémeaux; Daniel J Drucker; C Ronald Kahn; Jean Girard; Jean François Tanti; Nathalie M Delzenne; Catherine Postic; Rémy Burcelin
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Glucagon-like immunoreactivity in hypothalamic neurons of the rat.

Authors:  I Salazar; C Vaillant
Journal:  Cell Tissue Res       Date:  1990-08       Impact factor: 5.249

4.  Metabolic and endocrine functions of glucagon-like peptides - evolutionary and biochemical perspectives.

Authors:  T P Mommsen; E M Plisetskaya
Journal:  Fish Physiol Biochem       Date:  1993-07       Impact factor: 2.794

Review 5.  Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles.

Authors:  J M Conlon
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

Review 6.  PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation.

Authors:  Stefan Trapp; Simon C Cork
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-19       Impact factor: 3.619

Review 7.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Authors:  A Zarrinpar; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-10-11       Impact factor: 8.171

8.  Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.

Authors:  Lene Jessen; Benedikt A Aulinger; Jonathan L Hassel; Kyle J Roy; Eric P Smith; Todd M Greer; Stephen C Woods; Randy J Seeley; David A D'Alessio
Journal:  Endocrinology       Date:  2012-10-02       Impact factor: 4.736

Review 9.  Glucagon-like peptide 1 and appetite.

Authors:  Megan J Dailey; Timothy H Moran
Journal:  Trends Endocrinol Metab       Date:  2013-01-16       Impact factor: 12.015

10.  Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.

Authors:  Jason G Barrera; David A D'Alessio; Daniel J Drucker; Stephen C Woods; Randy J Seeley
Journal:  Diabetes       Date:  2009-09-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.